Rimegepant is an FDA-approved CGRP receptor antagonist that offers a new mechanism for treating acute migraine, particularly for patients who can't take triptans.
7 new CGRP drugsRimegepant is part of a wave of seven new migraine treatments targeting the CGRP pathway released within three years
What the researchers found
Rimegepant is a small molecule that blocks the CGRP receptor. It was developed based on the improved understanding of migraine as a neurovascular condition involving vasoactive peptides, particularly CGRP.
It is approved for acute treatment of migraine in adults with or without aura. In clinical trials, it decreased pain and reduced symptoms associated with migraine attacks.
Rimegepant is part of a wave of new migraine treatments in the past 3 years that includes:
- Acute treatments: lasmiditan, rimegepant, ubrogepant
- Preventive treatments: erenumab, fremanezumab, galcanezumab, eptinezumab
All of these target the neurovascular migraine pathway, with CGRP being the central peptide involved.
Why it matters
Most acute migraine treatments have been triptans, which do not work for everyone and are contraindicated in some patients with cardiovascular disease. CGRP receptor antagonists like rimegepant offer a new mechanism with a different safety profile, expanding options for migraine sufferers.
The numbers in context
Rimegepant 75 mg oral; FDA-approved for acute and preventive migraine; CGRP receptor antagonist
How the study worked
This is a narrative review covering the pharmacology, clinical evidence, and place in therapy of rimegepant for acute migraine treatment.
Who was studied
Adults with episodic migraine with or without aura (human)
What this study cannot tell us
This is a brief review without new clinical data. It does not deeply compare rimegepant to ubrogepant or triptans. Long-term safety data are still accumulating. Cost and insurance coverage remain barriers for many patients.
How to read the evidence
This review summarizes FDA-approved clinical evidence from phase 3 trials. While the review itself is narrative, rimegepant's approval was based on rigorous randomized controlled trials demonstrating efficacy and safety.
When this study was published
Published in 2021, this review captures rimegepant near its initial approval. Since then, additional evidence for preventive use and long-term safety has accumulated, further establishing the drug's clinical role.
The bigger picture
The discovery that CGRP drives migraine pathophysiology led to an entire new drug class — both small molecule antagonists (gepants like rimegepant) and monoclonal antibodies (like erenumab). This represents the first time migraine drugs were designed based on understanding the disease mechanism rather than discovered by chance. Rimegepant's dual approval for both acute and preventive use makes it uniquely versatile.
Questions still open
- How does rimegepant compare to ubrogepant and newer gepants in head-to-head studies?
- Is long-term daily rimegepant for prevention as safe as every-other-day dosing?
- Could CGRP-pathway drugs eventually replace triptans as first-line migraine treatment?
Common questions
What is CGRP and why does blocking it help migraines?
How is rimegepant different from triptans?
Read the original research
Rimegepant: acute treatment for migraine headaches.
Pain management, 11(3), 259-266
Citation
Peters, Golden L; Hennessey, Erin K. (2021). Rimegepant: acute treatment for migraine headaches.. Pain management, 11(3), 259-266. https://doi.org/10.2217/pmt-2020-0090